Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 13,445 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 13,445 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $909,688.70. Following the completion of the sale, the chief executive officer owned 3,818,512 shares in the company, valued at $258,360,521.92. The trade was a 0.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Monday, December 22nd, Christopher Richard Anzalone sold 12,586 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.44, for a total value of $861,385.84.
• On Wednesday, December 17th, Christopher Richard Anzalone sold 85,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $64.04, for a total transaction of $5,443,400.00.
• On Tuesday, December 16th, Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $62.58, for a total value of $3,397,968.84.
• On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $68.85, for a total transaction of $8,950,500.00.

Arrowhead Pharmaceuticals Trading Up 1.2%

Shares of Arrowhead Pharmaceuticals stock traded up $0.83 on Tuesday, reaching $69.83. 1,157,383 shares of the company were exchanged, compared to its average volume of 2,158,861. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $72.36. The firm has a market capitalization of $9.49 billion, a price-to-earnings ratio of -872.77 and a beta of 1.28. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a fifty day moving average price of $49.13 and a 200-day moving average price of $31.68.

Analyst Ratings Changes

ARWR has been the subject of several research reports. Morgan Stanley lifted their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a report on Wednesday, November 26th. Bank of America raised their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. The Goldman Sachs Group upped their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a report on Thursday, November 20th. Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Finally, Piper Sandler increased their target price on Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $61.89.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ARWR. Vanguard Group Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock valued at $553,077,000 after purchasing an additional 510,798 shares during the period. Avoro Capital Advisors LLC grew its holdings in Arrowhead Pharmaceuticals by 2.8% during the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after purchasing an additional 300,000 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after buying an additional 2,774,933 shares in the last quarter. Geode Capital Management LLC grew its stake in Arrowhead Pharmaceuticals by 1.0% in the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock valued at $47,067,000 after acquiring an additional 28,193 shares during the period. Finally, Marshall Wace LLP grew its position in shares of Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the period. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.